Going the distance: are we losing patients along the multiple myeloma treatment pathway?
Despite data suggesting that individuals with multiple myeloma can benefit from receiving several lines of therapy, and guidelines recommending treatment after relapse, a recent European patient chart review found that only 61% of patients receive second-line treatment. The review found that factors...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
29 March 2018
|
| In: |
Critical reviews in oncology, hematology
Year: 2018, Jahrgang: 126, Pages: 19-23 |
| ISSN: | 1879-0461 |
| DOI: | 10.1016/j.critrevonc.2018.03.021 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1016/j.critrevonc.2018.03.021 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S104084281730478X 
|
| Verfasserangaben: | Evangelos Terpos, Florence Suzan, Hartmut Goldschmidt |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1665342706 | ||
| 003 | DE-627 | ||
| 005 | 20230427000816.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190514s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.critrevonc.2018.03.021 |2 doi | |
| 035 | |a (DE-627)1665342706 | ||
| 035 | |a (DE-599)KXP1665342706 | ||
| 035 | |a (OCoLC)1341213101 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Terpos, Evangelos |d 1967- |e VerfasserIn |0 (DE-588)143650475 |0 (DE-627)704558181 |0 (DE-576)338175628 |4 aut | |
| 245 | 1 | 0 | |a Going the distance |b are we losing patients along the multiple myeloma treatment pathway? |c Evangelos Terpos, Florence Suzan, Hartmut Goldschmidt |
| 264 | 1 | |c 29 March 2018 | |
| 300 | |a 5 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 14.05.2019 | ||
| 520 | |a Despite data suggesting that individuals with multiple myeloma can benefit from receiving several lines of therapy, and guidelines recommending treatment after relapse, a recent European patient chart review found that only 61% of patients receive second-line treatment. The review found that factors such as old age and previous adverse events lead to physicians deciding not to treat after relapse. However, given the large number of regimens available, treatment can be tailored to individual patients’ needs and supportive care measures can help with the management of adverse effects. If approved therapies are not suitable for a patient, guidelines recommend registration in a clinical trial, yet only 7% of patients in the review were participating in such studies. A need for better education on the range of treatments available and their risk-benefit profiles is suggested. Access to new drugs should be examined to maximise the number of patients benefitting from them. | ||
| 650 | 4 | |a Adverse events | |
| 650 | 4 | |a Elderly | |
| 650 | 4 | |a European chart review | |
| 650 | 4 | |a Multiple myeloma | |
| 650 | 4 | |a Practice patterns | |
| 650 | 4 | |a Real-world practice | |
| 700 | 1 | |a Suzan, Florence |e VerfasserIn |4 aut | |
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Critical reviews in oncology, hematology |d Amsterdam [u.a.] : Elsevier Science, 1983 |g 126(2018), Seite 19-23 |h Online-Ressource |w (DE-627)320649024 |w (DE-600)2025731-4 |w (DE-576)094108137 |x 1879-0461 |7 nnas |a Going the distance are we losing patients along the multiple myeloma treatment pathway? |
| 773 | 1 | 8 | |g volume:126 |g year:2018 |g pages:19-23 |g extent:5 |a Going the distance are we losing patients along the multiple myeloma treatment pathway? |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.critrevonc.2018.03.021 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S104084281730478X |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190514 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |e 910000PG102258023X |e 910100PG102258023X |k 0/910000/ |k 1/910000/910100/ |p 3 |y j | ||
| 999 | |a KXP-PPN1665342706 |e 3475663228 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"person":[{"display":"Terpos, Evangelos","family":"Terpos","role":"aut","given":"Evangelos"},{"display":"Suzan, Florence","family":"Suzan","given":"Florence","role":"aut"},{"role":"aut","given":"Hartmut","family":"Goldschmidt","display":"Goldschmidt, Hartmut"}],"id":{"eki":["1665342706"],"doi":["10.1016/j.critrevonc.2018.03.021"]},"physDesc":[{"extent":"5 S."}],"name":{"displayForm":["Evangelos Terpos, Florence Suzan, Hartmut Goldschmidt"]},"recId":"1665342706","relHost":[{"origin":[{"publisherPlace":"Amsterdam [u.a.]","dateIssuedKey":"1983","publisher":"Elsevier Science","dateIssuedDisp":"1983-"}],"note":["Gesehen am 04.02.20"],"pubHistory":["1.1983/84 -"],"title":[{"title":"Critical reviews in oncology, hematology","title_sort":"Critical reviews in oncology, hematology"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Going the distance are we losing patients along the multiple myeloma treatment pathway?Critical reviews in oncology, hematology","recId":"320649024","physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2025731-4"],"issn":["1879-0461"],"eki":["320649024"]},"language":["eng"],"part":{"extent":"5","text":"126(2018), Seite 19-23","volume":"126","pages":"19-23","year":"2018"}}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title_sort":"Going the distance","subtitle":"are we losing patients along the multiple myeloma treatment pathway?","title":"Going the distance"}],"note":["Gesehen am 14.05.2019"],"origin":[{"dateIssuedDisp":"29 March 2018","dateIssuedKey":"2018"}]} | ||
| SRT | |a TERPOSEVANGOINGTHEDI2920 | ||